E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Strategies to prolong remission duration in elderly patients with MCL are urgently needed. The effects of Rapamycin derivates on MCL cells in vitro and the evolving in vivo data support the further investigation of RAD001 in this incurable disease |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To investigate the efficacy (time to progression) and safety of a
maintenance therapy with Everolimus in patients with MCL aged
over 60 years or aged over 40 years but who are not eligible for high
dose chemotherapy followed by autologous stem cell support or
allogeneic stem cell transplantation |
|
E.2.2 | Secondary objectives of the trial | |
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Patients with a proven history of mantle cell lymphoma
2. Patients with achieved disease control after one to four lines
of chemotherapy (complete response, partial response, stable
disease) for mantle cell lymphoma.
3. Patients must have been treated with a CHOP-like
chemotherapy or a Fludarabine-containing regimen
previously and Rituximab must have been used as part of the
previous treatment.
4. Age ≥ 60 years or patients ≥40 and <60 years of age who are
not eligible for high dose chemotherapy followed by
autologous stem cell support or allogeneic stem cell
transplantation.
5. Minimum of two weeks since any major surgery, completion
of radiation, or completion of all prior systemic anticancer
therapy (adequately recovered from the acute toxicities of
any prior therapy).
6. WHO performance status ≤ 2
Adequate bone marrow function as shown by: ANC ≥ 1.5 x
109/L, Platelets ≥ 100 x 109/L, Hgb > 9 g/dL
8. Adequate liver function as shown by: serum bilirubin ≤ 1.5 xupper limit of normal (ULN), and serum transaminases
activity ≤ 3 x ULN. With the exception of serum
transaminases (< 5 x ULN) if the patient has liver metastases
9. Life expectancy of at least 3 months
10. Signed informed consent |
|
E.4 | Principal exclusion criteria |
- Prior treatment with any investigational drug within the
preceding 4 weeks
2. Chronic treatment with systemic steroids or another
immunosuppressive agent except for Rituximab.
3. Uncontrolled brain or leptomeningeal disease manifestation,
including patients who continue to require glucocorticoids
for brain or leptomeningeal disease manifestation
4. Other malignancies within the past 3 years except for
adequately treated carcinoma of the cervix or basal or
squamous cell carcinomas of the skin.
5. Other concurrent severe and/or uncontrolled medical disease
which could compromise participation in the study (i.e.,
uncontrolled diabetes, uncontrolled hypertension, severe
infection, severe malnutrition, unstable angina, or congestive
heart failure - New York Heart Association Class III or IV,
ventricular arrhythmias active ischemic heart disease,
myocardial infarction within six months, chronic liver or
renal disease, active upper GI tract ulceration, psychiatric
disease)
6. A known history of HIV seropositivity
7. History or serology indicating active or chronic Hepatitis B
or C or detection of viral DNA (Hep. B or C) via PCR
8. Impairment of gastrointestinal function or gastrointestinal
disease that may significantly alter the absorption of
EVEROLIMUS (e.g., ulcerative disease, uncontrolled
nausea, vomiting, diarrhea, malabsorption syndrome or small
bowel resection)
9. Patients with an active, bleeding diathesis or on oral antivitamin
K medication (except low dose coumarin)
10. Previous organ transplantation.
11. Women who are pregnant or breast feeding, or women able
to conceive and unwilling to practice an effective method of
birth control. (Women of childbearing potential must have a
negative urine or serum pregnancy test within 7 days prior to
administration of EVEROLIMUS). Oral, implantable, orinjectable contraceptives may be affected by cytochrome
P450 interactions, and are therefore not considered effective
for this study. A highly effective methode of birth control is
defined as those which results in a low failure rate (i.e. less
than 1% per year) for example sexual abstinence or
vasectomised partner.
12. Patients who have received prior treatment with an mTor
inhibitor.
13. History of noncompliance to medical regimens
14. Patients unwilling to or unable to comply with the protocol
15. Patients with galactose intolerance, lack of lactase or
malabsorption of glucose or galactose |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Time to progression despite maintenance therapy with everolimus.
Start of measurement is defined as last day of application of remission-inducing chemotherapy. |
|
E.5.2 | Secondary end point(s) |
To analyze toxicity and feasibility of a treatment with
EVEROLIMUS in patients with MCL after first, second,
third and fourth line chemotherapy
• To analyze surrogate parameters involved in angiogenesis
and cell-cycle regulation in patients with circulating MCL
cells or bone marrow involvement (only in patients
with circulating MCL cells or with bone marrow
involvement)
• To compare the duration of previous responses with the
duration of responses in patients with maintenance therapy.
• To analyze the conversion rate in MCL patients during
maintenance therapy (improvement of partial to complete
response, stable disease to partial or complete response).
• To analyze the overall survival of patients with maintenance
therapy.
• To analyze Quality of life during maintenance therapy |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | Information not present in EudraCT |
E.7.1.2 | Bioequivalence study | Information not present in EudraCT |
E.7.1.3 | Other | Information not present in EudraCT |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Information not present in EudraCT |
E.8.1.2 | Open | Information not present in EudraCT |
E.8.1.3 | Single blind | Information not present in EudraCT |
E.8.1.4 | Double blind | Information not present in EudraCT |
E.8.1.5 | Parallel group | Information not present in EudraCT |
E.8.1.6 | Cross over | Information not present in EudraCT |
E.8.1.7 | Other | Information not present in EudraCT |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 10 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Reasons that a patient may discontinue participation in a clinical study are considered to constitute one of the
following:
disease progression
• protocol violation
• subject withdrew consent
• lost to follow-up
• administrative problems
• death |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 6 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |